

NEW SMALL MOLECULE DRUG LEAD FOR EPILEPSY GAIUS THERAPEUTICS

THE PROBLEM

50 million people are affected by epilepsy world-wide.

Only 64% of patients respond to the available anti-epileptics, which often have undesirable side effects.

OUR SOLUTION

We have discovered the small molecule TMC-120B as a CNS active drug lead. We have data supporting that TMC-120B works through a new mode-of-action.

PATENT STATUS

DTU & KU Leuven have joint patents in both EU and US

FINANCIAL OVERVIEW

Biotech business model. Soft funding, followed by VC funding for preclinical and early clinical development.

MILESTONES

CNS target(s) of TMC-120B validated.

In vivo evidence for the mode-of-action.

TARGET MARKET & CUSTOMERS

Partnering with or exit to Pharma.

Maturing and de-risking through investments.

CO-FOUNDER PROFILE

Preferred qualifications

- Fundraising and leading investor dialogues. Desire to take lead of commercial development in collaboration with the team at DTU.
- Experience with drug development from Biotech/Pharma.

Personal fit

- Bring a commercial mindset, drive soft and hard fundraising.
- Patience working with an early project

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Get to know the technology.

Scout initial soft funding options.

Identify KOLs and clinical stakeholders for the main applications.

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

Thomas O. Larsen: Professor, PhD, DTU.
Has co-founded Chromologics Aps

Mads H. Clausen, Professor, PhD, DTU.
Has co-founded three spin-outs.
Works with co-founders on two other projects

Daniëlle Copmanns: Assistant Professor
Laboratory for Molecular Biodiscovery
KU Leuven, Belgium,
New as co-founder



ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship (OE) is a collaboration between all Danish universities aiming to create more research-based startups.